Reta GLP-3

Research Use Only

All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.

Retatrutide Overview

Retatrutide is a synthetic peptide engineered to function as a multi-receptor agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor pathways. Due to its activity across multiple signaling systems, Retatrutide has become an important research tool for studying receptor pharmacology, metabolic signaling networks, endocrine regulation, and pathway interactions in laboratory and preclinical models.

Research has examined its receptor-binding characteristics, downstream signaling activity, and effects on integrated metabolic pathways, making it valuable for investigations into complex hormonal signaling mechanisms.

Coskun T. et al. (2022).

History

The development of Retatrutide followed advances in incretin-based peptide research and the growing interest in multi-target receptor agonists. Early studies of GLP-1 and GIP receptor signaling demonstrated the importance of these pathways in endocrine regulation and metabolic physiology. Researchers later explored the addition of glucagon receptor activity to create a triple-agonist platform capable of engaging multiple signaling pathways simultaneously.

Retatrutide was subsequently developed as a next-generation investigational peptide designed to activate GLP-1, GIP, and glucagon receptors within a single molecular structure, providing researchers with a tool for studying receptor cross-talk, signaling integration, and endocrine pathway dynamics.

Coskun T. et al. (2022).

Retatrutide Structure

Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: 4731.3 g/mol

Research Findings

Retatrutide has been studied extensively in preclinical and experimental models focused on receptor pharmacology, endocrine signaling, and metabolic pathway characterization. Research highlights its ability to activate multiple receptor systems while providing insights into signaling integration across interconnected physiological pathways.

Studies have reported activity across GLP-1, GIP, and glucagon receptor pathways, enabling researchers to investigate downstream signaling cascades, receptor selectivity, pathway interactions, and systemic biological responses.

Key Areas of Research:

Signaling: Multi-receptor activation, pathway dynamics, receptor cross-talk

Endocrine: Incretin signaling, glucagon pathway characterization, hormonal regulation

Metabolic: Energy balance pathways, signaling integration, metabolic physiology models

Together, these findings suggest broad experimental potential for Retatrutide in studies of receptor pharmacology, endocrine biology, and integrated signaling networks. By simultaneously engaging GLP-1, GIP, and glucagon receptor systems, Retatrutide provides researchers with a versatile platform for investigating complex pathway interactions and systemic signaling responses in laboratory settings.

Jastreboff A.M. et al. (2023)

References

Coskun, T., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for the treatment of obesity. Cell Metabolism, 34(6), 888–903.

Jastreboff, A.M., et al. (2023). Triple-hormone-receptor agonist Retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514–526.

Muller, T.D., Finan, B., Bloom, S.R., et al. (2018). Triagonists uncover an expanded therapeutic role for glucagon. Nature Reviews Drug Discovery, 17(6), 403–421.